Complement Therapeutics GmbH (CTx) is a German headquartered early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for GA, a leading cause of blindness. Additional programs will evaluate potential therapeutic opportunities in other complement-mediated conditions
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable the quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
The Company has subsidiaries in the UK (Complement Therapeutics Ltd) and in the USA (Complement Therapeutics Inc) as well as research laboratories in Stevenage, UK.